Thus, clinical trials testing prospective STING immunotherapy agents should also consider measuring cancer-associated comorbidities, including parameters of functional impairment and pain, as improving the quality of life in cancer patients is equally important as extending the duration of survival. Here, STING1 is linked to cancer.